A comparison of fecal occult-blood tests for colorectal-cancer screening.

BACKGROUND Hemoccult II, a widely used guaiac test for fecal occult blood, has a low sensitivity for detecting colorectal neoplasms in asymptomatic patients at average risk. In such patients, the performance characteristics of screening tests developed to improve on Hemoccult II are not known. METHODS A set of three fecal occult-blood tests--Hemoccult II; Hemoccult II Sensa, a more sensitive guaiac test; and HemeSelect, an immunochemical test for human hemoglobin--was mailed to all patients 50 years of age or older who were scheduled for personal health appraisals at the Kaiser Permanente Medical Center in Oakland, California. The performance of each test and of a combination test (HemeSelect to confirm positive Hemoccult II Sensa results) was evaluated by identifying screened patients who had colorectal neoplasma (carcinoma or a polyp > or = 1 cm in diameter) in the two years after screening. RESULTS Of the 10,702 eligible patients, 8104 (75.7 percent) had at least one interpretable sample and were screened on the basis of at least one test; 96 percent of these patients had complete two-year follow-up. The sensitivity of the tests for detecting carcinoma was lowest with Hemoccult II (37.1 percent; 95 percent confidence interval, 19.7 to 54.6 percent), intermediate with the combination test (65.6 percent; 95 percent confidence interval, 47.6 to 83.6 percent) and with HemeSelect (68.8 percent; 95 percent confidence interval, 51.1 to 86.4 percent), and highest with Hemoccult II Sensa (79.4 percent; 95 percent confidence interval, 64.3 to 94.5 percent). The specificity for detecting carcinoma was 86.7 percent with Hemoccult II Sensa, 94.4 percent with HemeSelect, 97.3 percent with the combination test, and 97.7 percent with Hemoccult II. HemeSelect and the combination test detected more colorectal carcinomas and polyps than Hemoccult II, with only slight increases in the number of colonoscopies needed. CONCLUSIONS HemeSelect and a combination test in which HemeSelect is used to confirm positive Hemoccult II Sensa results improve on Hemoccult II in screening patients for colorectal carcinoma.

[1]  A. Munakata,et al.  Endoscopic and histologic correlates of colorectal polyp bleeding. , 1995, Gastrointestinal endoscopy.

[2]  B. Flehinger,et al.  Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. , 1993, Journal of the National Cancer Institute.

[3]  P. Lance,et al.  Fecal occult blood tests: what's new? , 1993, Gastroenterology.

[4]  F. Macrae,et al.  Evaluation of new occult blood tests for detection of colorectal neoplasia. , 1993, Gastroenterology.

[5]  L M Schuman,et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. , 1993, The New England journal of medicine.

[6]  J. Cuzick,et al.  Prevention of colorectal cancer by once-only sigmoidoscopy , 1993, The Lancet.

[7]  K. Okazaki,et al.  Major histocompatibility antigen-restricted cytotoxicity in inflammatory bowel disease. , 1993, Gastroenterology.

[8]  G. Friedman,et al.  Effect of Fecal Occult Blood Testing on Mortality from Colorectal Cancer: A CaseControl Study , 1993, Annals of Internal Medicine.

[9]  R. Feldman,et al.  Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. , 1990, Annals of internal medicine.

[10]  J. B. Simon.  Occult blood screening for colorectal carcinoma: a critical review. , 1985, Gastroenterology.

[11]  S. Winawer,et al.  Sensitivity and specificity of the fecal occult blood test for colorectal neoplasia. , 1982, Gastroenterology.

[12]  F. Macrae,et al.  Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. , 1982, Gastroenterology.

[13]  W. Grove.  Statistical Methods for Rates and Proportions, 2nd ed , 1981 .

[14]  A. Morrison,et al.  Basic issues in population screening for cancer. , 1980, Journal of the National Cancer Institute.